Basilea Pharmaceutica (LTS:0QNA) Debt-to-Equity : -12.86 (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Basilea Pharmaceutica Debt-to-Equity?

Basilea Pharmaceutica's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was CHF17.5 Mil. Basilea Pharmaceutica's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was CHF111.1 Mil. Basilea Pharmaceutica's Total Stockholders Equity for the quarter that ended in Dec. 2023 was CHF-10.0 Mil. Basilea Pharmaceutica's debt to equity for the quarter that ended in Dec. 2023 was -12.86.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Basilea Pharmaceutica's Debt-to-Equity or its related term are showing as below:

LTS:0QNA' s Debt-to-Equity Range Over the Past 10 Years
Min: -12.86 Med: -3.74 Max: 13.11
Current: -12.86

During the past 13 years, the highest Debt-to-Equity Ratio of Basilea Pharmaceutica was 13.11. The lowest was -12.86. And the median was -3.74.

LTS:0QNA's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.145 vs LTS:0QNA: -12.86

Basilea Pharmaceutica Debt-to-Equity Historical Data

The historical data trend for Basilea Pharmaceutica's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Basilea Pharmaceutica Debt-to-Equity Chart

Basilea Pharmaceutica Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

-2.14

-2.38

-3.74

-9.03

-12.86

Basilea Pharmaceutica Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															-3.74	-3.44	-9.03	11.33	-12.86

Competitive Comparison of Basilea Pharmaceutica's Debt-to-Equity

For the Biotechnology subindustry, Basilea Pharmaceutica's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Basilea Pharmaceutica's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Basilea Pharmaceutica's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Basilea Pharmaceutica's Debt-to-Equity falls into.

Basilea Pharmaceutica Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Basilea Pharmaceutica's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(17.515	+	111.091)	/	-10.002
	=	-12.86

Basilea Pharmaceutica's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(17.515	+	111.091)	/	-10.002
	=	-12.86

Basilea Pharmaceutica (LTS:0QNA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Basilea Pharmaceutica Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Basilea Pharmaceutica's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Basilea Pharmaceutica (LTS:0QNA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Basilea Pharmaceutica Ltd (LTS:0QNA) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

BSLNz:UK BSLN:Switzerland

Address

Switzerland Innovation Park, Basel Area, Main Campus, Near Basel, Allschwil, CHE, 4058

Website

https://www.basilea.com

Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.

Basilea Pharmaceutica (LTS:0QNA) Headlines

No Headlines